NL

Nanna Luneborg

General Partner at Forbion

Amsterdam, North Holland

Invests in

Stages:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

2021

  • General Partner

    2021

    - General Partner, Forbion Growth Opportunities Fund - Late stage and crossover investments in biotech - Board director of Capstan, BioInvent, F2G, Noema and Inversago (acquired by Novo Nordisk), observer in Numab

2012 - 2021

  • Partner

    2018 - 2021

    • Partner in Novo Ventures • Board director in Numab, Lava (LVTX), ReViral (acquired by Pfizer), NodThera and Stargazer • Previous deals as lead investor/board director include NBE Therapeutics (acquired by Boehringer Ingelheim), Inventiva (IVA), Orphazyme (ORPHA), ObsEva (OBSV) and IO Biotech (IOBT)

  • Principal

    2016 - 2017

    • Principal in Novo Ventures

  • Investment Director

    2013 - 2015

    • Investment Director in Novo Seeds • Board member in IO Biotech, Inthera, Glionova, Affinicon, MinervaX, Pcovery, board observer in Galecto, ForEndo

  • Principal

    2012 - 2013

    • Principal in Novo Seeds • Seed stage biotech venture investment in Northern Europe

2008 - 2012

  • Associate

    2008 - 2012

    • Investment professional in a healthcare venture fund • Successful exits from both primary and secondary deals, incl Convergence, Ulthera, SureCalm • Multiple deals completed from initial diligence to closing • Various deal structures: primary/secondary investments, spin-out, start-up, management buy-in

2008 - 2008

  • Intern

    2008 - 2008

    MBA summer internship

2008 - 2008

  • Consulting project

    2008 - 2008

    MBA team consulting project: IP technology in UK healthcare

2007 - 2007

  • Consulting project

    2007 - 2007

    MBA team consulting project on business model and strategy for a biotech start-up

2005 - 2007

  • Senior Business Intelligence Analyst

    2006 - 2007

    • Business Intelligence on performance metrics across £315 M research portfolio • Strategic evaluation to CEO

  • Research Manager

    2005 - 2006

    • Financial and scientific analyses of research portfolio across organisation • Liaison with principal investigators and research organisations in UK and US

  • Graduate Research Associate

    2000 - 2004

    Research project leading to PhD thesis in development neuroscience

1996 - 1997

  • Marketing Manager

    1996 - 1997

    Managed marketing campaigns for international business conference and training group